Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation treatment for cystic fibrosis (CF).
The agreement follows a positive final draft recommendation from NICE and ensures access for all eligible patients in England.
ALYFTREK is licensed for people aged six and older with at least one F508del mutation or another responsive mutation in the CFTR gene. It is Vertex’s fifth CF medicine and offers a once-daily oral option.
Ludovic Fenaux, Senior Vice President, Vertex International, said: “We’re proud that ALYFTREK, our fifth CF medicine, is available today as another treatment option for all eligible CF patients in England. It represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease.”
He added: “In our pivotal studies, ALYFTREK demonstrated the potential for even better outcomes for patients than KAFTRIO. We’re pleased to have reached this agreement with NHS England that recognises the value that this new medicine brings to CF patients, their families and society.”
ALYFTREK has already received European regulatory approval, with patients in Ireland, Denmark and Germany among the first to gain access.
Vertex is continuing discussions with reimbursement bodies across the European Union to expand access to eligible patients as quickly as possible.
The agreement marks a major step forward in CF care, offering improved outcomes and greater convenience for patients managing this lifelong condition.
